Okami Medical is a private MedTech company focused on embolization solutions, and this weekly recap highlights expanding clinical use and conference visibility for its LOBO platform. The company reported a new real-world case in which interventional radiologist Dr. Ahmad Hashmi used the LOBO-9 device to treat an 86-year-old patient with splenic trauma, achieving rapid vessel occlusion through a guide catheter without additional embolic devices.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The case underscores LOBO’s positioning as a tool designed to improve procedural speed and efficiency, particularly in high-acuity trauma settings where minimizing device count can have workflow and cost benefits. Growing use in such complex scenarios may reinforce clinician confidence in LOBO and support broader adoption across interventional radiology practices.
Okami Medical also continued to spotlight its LOBO HDBRAID peripheral embolization device around the GEST 2026 endovascular conference in New York. The company emphasized that LOBO HDBRAID is engineered to enable fast, complete, often single-device occlusions across a range of peripheral vascular cases.
At GEST 2026, Okami is showcasing LOBO HDBRAID at Booth 114 and organizing hands-on workshops and masterclasses focused on coils, plugs, and stent grafts. This education-centric approach aims to deepen physician engagement, providing practical exposure that could translate into higher procedure volumes and improved product pull-through over time.
These developments build on prior weeks’ clinical case reports, including complex renal arteriovenous malformation and pulmonary aneurysm interventions that highlighted LOBO’s versatility and efficiency. Together, the growing body of case-based evidence and targeted conference marketing suggest steady momentum for the LOBO platform and a continued focus on complex vascular interventions.
From a strategic standpoint, expanded real-world use and specialized conference presence strengthen Okami Medical’s positioning in the embolization and interventional radiology markets, even though detailed financial metrics and broad clinical data remain limited publicly. Overall, this was a constructive week for Okami Medical, marked by additional clinical validation and ongoing commercialization efforts for its LOBO embolization technology.